Synergistic enhancement of iron oxide nanoparticle and gadolinium for dual-contrast MRI

Biochemical and Biophysical Research Communications

Volumn 425, Issue 4, 2012, Pages 886-891

  Zhang, Fan ^a,c   Huang, Xinglu ^a   Qian, Chunqi ^b,c   Zhu, Lei ^a,c   Hida, Naoki ^a   Niu, Gang ^a,d   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c XIAMEN UNIVERSITY   (China)

^d NONE   (United States)

Author keywords

Dual contrast; Gd DTPA; Iron oxide; MRI; RGD

Indexed keywords

CARBON; GADOLINIUM; GADOLINIUM PENTETATE; IRON OXIDE; NANOPARTICLE; NITROGEN;

ANIMAL CELL; ARTICLE; BRAIN DAMAGE; BRAIN TUMOR; CONTRAST ENHANCEMENT; LYMPH NODE METASTASIS; LYMPHOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANIMALIA;

EID: 84865996017     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.168     Document Type: Article

References (30)

1. Rudin M., Weissleder R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2003, 2:123-131.
2. Meade T.J., Taylor A.K., Bull S.R. New magnetic resonance contrast agents as biochemical reporters. Curr. Opin. Neurobiol. 2003, 13:597-602.
3. Weissleder R. Liver MR imaging with iron oxides: toward consensus and clinical practice. Radiology 1994, 193:593-595.
4. Yu M.K., Park J., Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012, 2:3-44.
5. Lee H., Lee E., Kim K., et al. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J. Am. Chem. Soc. 2006, 128:7383-7389.
6. B.M. Seddon, P. Workman, The role of functional and molecular imaging in cancer drug discovery and development, Br. J. Radiol. 76 Spec No. 2 (2003) S128-S138.
7. Seneterre E., Taourel P., Bouvier Y., et al. Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996, 200:785-792.
8. Bulte J.W., Kraitchman D.L. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004, 17:484-499.
9. Zhuo J., Gullapalli R.P. AAPM/RSNA physics tutorial for residents: MR artifacts, safety, and quality control. Radiographics 2006, 26:275-297.
10. Macarini L., Marini S., Milillo P., et al. Double-contrast MRI (DC-MRI) in the study of the cirrhotic liver: utility of administering Gd-DTPA as a complement to examinations in which SPIO liver uptake and distribution alterations (SPIO-LUDA) are present and in the identification and characterisation of focal lesions. Radiol. Med. 2006, 111:1087-1102.
11. Semelka R.C., Lee J.K., Worawattanakul S., et al. Sequential use of ferumoxide particles and gadolinium chelate for the evaluation of focal liver lesions on MRI. J. Magn. Reson. Imaging 1998, 8:670-674.
12. Weissleder R., Saini S., Stark D.D., et al. Dual-contrast MR imaging of liver cancer in rats. AJR Am. J. Roentgenol. 1988, 150:561-566.
13. Ward J., Guthrie J.A., Scott D.J., et al. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 2000, 216:154-162.
14. Bolog N., Pfammatter T., Mullhaupt B., et al. Double-contrast magnetic resonance imaging of hepatocellular carcinoma after transarterial chemoembolization. Abdom. Imaging 2008, 33:313-323.
15. Suto Y., Shimatani Y., Kato T., et al. Double contrast MR imaging with iron colloid and Gd-DTPA in cholangiocellular carcinoma. Acta. Radiol. 1994, 35:632-633.
16. Zhang F., Huang X., Zhu L., et al. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 2012, 33:5414-5422.
17. F. Zhang, L. Zhu, X. Huang, et al., Differentiation of reactive and tumor metastatic lymph nodes with diffusion-weighted and SPIO-enhanced MRI. Mol. Imaging Biol., 2012 May 16. [Epub ahead of print].
18. Henkelman R.M., Hardy P., Poon P.Y., et al. Optimal pulse sequence for imaging hepatic metastases. Radiology 1986, 161:727-734.
19. Denys A., Arrive L., Servois V., et al. Hepatic tumors: detection and characterization at 1-T MR imaging enhanced with AMI-25. Radiology 1994, 193:665-669.
20. Hagspiel K.D., Neidl K.F., Eichenberger A.C., et al. Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995, 196:471-478.
21. Shimizu A., Ito K., Koike S., et al. Cirrhosis or chronic hepatitis: evaluation of small (< or =2-cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology 2003, 226:550-555.
22. Nakamura H., Ito N., Kotake F., et al. Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma. J. Gastroenterol. 2000, 35:849-855.
23. Misselwitz B. MR contrast agents in lymph node imaging. Eur. J. Radiol. 2006, 58:375-382.
24. Vassallo P., Matei C., Heston W.D., et al. AMI-227-enhanced MR lymphography: usefulness for differentiating reactive from tumor-bearing lymph nodes. Radiology 1994, 193:501-506.
25. Weissleder R., Elizondo G., Josephson L., et al. Experimental lymph node metastases: enhanced detection with MR lymphography. Radiology 1989, 171:835-839.
26. Moghimi S.M., Bonnemain B. Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography. Adv. Drug Deliv. Rev. 1999, 37:295-312.
27. Suga K., Yuan Y., Ogasawara N., et al. Localization of breast sentinel lymph nodes by MR lymphography with a conventional gadolinium contrast agent. Preliminary observations in dogs and humans. Acta Radiol. 2003, 44:35-42.
28. Niu G., Chen X. Why integrin as a primary target for imaging and therapy. Theranostics 2011, 1:30-47.
29. Chen X. Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev. Med. Chem. 2006, 6:227-234.
30. Ye Y., Chen X. Integrin targeting for tumor optical imaging. Theranostics 2011, 1:102-126.